Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

NCT ID: NCT07149363

Last Updated: 2026-01-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-28
• Study Completion Date: 2030-07-31

Brief Summary

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

Detailed Description

This is a phase II open-label, single-arm, multi-center study to evaluate the efficacy and safety of adjuvant immunotherapy with chemotherapy for completely resected pathologic T1-T2, N0-N1, M0 small cell lung cancer (SCLC). The statistical design includes a predefined range of alpha and power to detect an improvement in 2-year disease free survival (DFS).

Conditions

Small Cell Lung Cancer (SCLC)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Durvalumab and one of the two chemotherapy combinations: cisplatin or carboplatin, and etoposide

65 participants will be enrolled.

Group Type: EXPERIMENTAL

Durvalumab 50 MG/ML

Intervention Type: DRUG

Following surgical removal of their small-cell lung cancer, participants will receive a combination of 1500 mg durvalumab and cisplatin 75 mg/m2 or carboplatin AUC 5 on day 1, and etoposide 100 mg/m2 on days 1, 2, and 3, every 3 weeks for 4 cycles (a total of 12 weeks). Following the combination of chemotherapy and immunotherapy, participants will then receive 1500 mg durvalumab every 4 weeks for 9 cycles (a total of 36 weeks).

Interventions

Durvalumab 50 MG/ML

Following surgical removal of their small-cell lung cancer, participants will receive a combination of 1500 mg durvalumab and cisplatin 75 mg/m2 or carboplatin AUC 5 on day 1, and etoposide 100 mg/m2 on days 1, 2, and 3, every 3 weeks for 4 cycles (a total of 12 weeks). Following the combination of chemotherapy and immunotherapy, participants will then receive 1500 mg durvalumab every 4 weeks for 9 cycles (a total of 36 weeks).

Intervention Type: DRUG

Other Intervention Names

Imfinzi®; MEDI4736

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years.
• Body weight >30 kg.
• Must have a life expectancy of at least 12 weeks.
• Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee on Cancer staging system, 8th edition.
• Have completely resected (wedge resection, segmentectomy, lobectomy, sleeve lobectomy, bilobectomy, or pneumonectomy) small-cell lung cancer within 78 days of enrollment.
• Complete mediastinal lymph node dissection (MLND) or systematic mediastinal lymph node sampling is required.
• No prior systemic therapies, for small cell lung cancer.
• Post-operative radiation for the resected small cell lung cancer is acceptable per treating physician in the setting of N1 disease, but no other prior radiation for small cell lung cancer.
• ECOG performance status 0-1.

Exclusion Criteria

• Patients who are receiving any other investigational agents.
• Concurrent enrollment in another clinical study involving investigational treatment directed to treatment of patients with small cell lung cancer.
• Prior treatment with durvalumab.
• History of another primary malignancy except for:

• Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP and of low potential risk for recurrence.
• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
• Superficial bladder cancer without active disease after treatment.
• Low grade prostate cancer without indication for active treatment.
• Adequately treated carcinoma in situ without evidence of disease.
• Patients with a history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis (DVT) within the past 3 months.
• Patients with hemoptysis in excess of 2.5 mL within 2 weeks prior to the first dose of study medication.
• Patients requiring concomitant therapy with phenytoin, phenobarbital, or carbamazepine.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Alliance Foundation Trials, LLC.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chi-Fu Jeffrey Yang, MD

Role: STUDY_CHAIR

Massachusetts General Hospital

Jacob Sands, MD

Role: STUDY_CHAIR

Dana-Farber Cancer Institute

Evanthia Galanis, MD

Role: PRINCIPAL_INVESTIGATOR

Alliance Foundation Trials, LLC.

Central Contacts

Quality Management and Compliance

Role: CONTACT

ClinicalTrials.Queries@alliancefoundationtrials.org

617-732-8727

Other Identifiers

AFT-61

Identifier Type: -

Identifier Source: org_study_id